APA (7th ed.) Citation

Kawczak, P., & Bączek, T. (2026). Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. Journal of Clinical Medicine, 15(12), 4425. https://doi.org/10.3390/jcm15124425

Chicago Style (17th ed.) Citation

Kawczak, Piotr, and Tomasz Bączek. "Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat." Journal of Clinical Medicine 15, no. 12 (2026): 4425. https://doi.org/10.3390/jcm15124425.

MLA (9th ed.) Citation

Kawczak, Piotr, and Tomasz Bączek. "Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody–Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat." Journal of Clinical Medicine, vol. 15, no. 12, 2026, p. 4425, https://doi.org/10.3390/jcm15124425.